Home > News > SpeciGen Signs Agreement with MSU
May 1st, 2006
SpeciGen Signs Agreement with MSU
Abstract:
SpeciGen announced today that they have signed an exclusive license agreement with Montana State University (MSU), Bozeman, Montana for intellectual property covering novel protein cage based nanotechnologies. SpeciGen CEO Lonnie Bookbinder stated: "This license allows SpeciGen to initiate research, development and manufacturing disciplines with a well developed technology for targeted delivery of novel diagnostic and therapeutic drugs."
Source:
pharmalive.com
Bookmark:
| Related Links |
Center for Bio-Inspired Nanomaterials
| Related News Press |
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Patents/IP/Tech Transfer/Licensing
Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023
Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||